Skip to main content
SpringerLink
Log in

Pharmacoeconomic Impact of Low-Dose Macrogol 3350 plus Electrolytes Compared with Lactulose in the Management of Chronic Idiopathic Constipation among Ambulant Patients in Belgium

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Objective

To estimate the economic impact of using low-dose macrogol 3350 plus electrolytes (macrogol 3350; Movicol®) compared with lactulose in the treatment of chronic idiopathic constipation among ambulant patients in Belgium, from the perspectives of the Sick Fund and patients. The analysis considered separately the economic impact of (a) a specialist and (b) a general practitioner (GP) initiating treatment.

Design and setting

This was a modelling study performed from the perspective of Belgium’s Sick Fund and patients.

Methods

Estimates of healthcare resource utilisation in a previously reported UK model depicting the management of chronic idiopathic constipation with either macrogol 3350 and lactulose over 3 months were replaced with Belgian estimates derived from a panel of 11 gastroenterologists and 11 GPs. The model was used to estimate the expected 3-monthly Sick Fund cost and direct cost to patients of using either laxative to manage chronic idiopathic constipation in Belgium.

Main outcome measures and results

According to our model, 53% and 24% of patients are expected to be successfully treated with macrogol 3350 and lactulose, respectively. Additionally, using macrogol 3350 instead of lactulose is expected to reduce the 3-monthly Sick Fund cost in approximately 55% of patients and afford a cost-effective treatment in the remaining patients. Furthermore, the 3-monthly Sick Fund cost of managing chronic idiopathic constipation among ambulant patients is expected to be reduced by approximately 50% if patients were initially treated by a GP instead of a specialist. In Belgium, laxatives are paid for by patients. Despite the difference in their acquisition cost, treating chronic idiopathic constipation with either macrogol 3350 or lactulose was found to be cost neutral from a patient’s perspective.

Conclusions

The true cost of managing chronic idiopathic constipation is impacted on by a broad range of resources and not only laxative acquisition costs. This study indicated that managing ambulant patients with chronic idiopathic constipation with macrogol 3350 instead of lactulose is a cost-effective treatment from the Sick Fund’s perspective and cost neutral from a patient’s perspective.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Table II
Table III

Similar content being viewed by others

References

  1. Barloon T, Lu C. Diagnostic imaging in the evaluation of constipation in adults. Am Fam Physician 1997; 56(2): 513–20

    PubMed  CAS  Google Scholar 

  2. Ross H. Constipation: cause and control in an acute hospital setting. Br J Nurs 1998; 7(15): 907–13

    PubMed  CAS  Google Scholar 

  3. Powell M, Davies C. Constipation: a management overview. Audit of chronic constipation in the community. London: Professional Medical Communications Ltd, 1999: 1–5

    Google Scholar 

  4. Kinnunen O, Winblad I, Koistinen P, et al. Safety and efficacy of a bulk laxative containing senna versus lactulose in the treatment of chronic constipation in geriatric patients. Pharmacology 1993; 47 Suppl. 1: 253–5

    Article  PubMed  Google Scholar 

  5. Intercontinential Medical Statistics (IMS). London: 1991

  6. Verhaeghe J, Jaecques N, Rombouts J, et al. Functional dyspepsia versus other functional gastrointestinal disorders: a practical approach in Belgian general practices. Scand J Gastroenterol 1993; 195: 25–34

    Article  CAS  Google Scholar 

  7. Health Care Systems in Transition: Belgium, 2000. European Observatory on Health Care Systems. Copenhagen: WHO Regional Office for Europe

    Google Scholar 

  8. Christie AH, Culbert P, Guest JF. The economic impact of low dose polyethylene glycol 3350 plus electrolytes compared to lactulose in the management of idiopathic constipation in the UK. Pharmacoeconomics 2002; 20(1): 49–60

    Article  PubMed  Google Scholar 

  9. Attar A, Lémann M, Ferguson A, et al. Comparison of a low dose polyethylene glycol electrolyte solution with lactulose for treatment of chronic constipation. Gut 1999; 44: 226–30

    Article  PubMed  CAS  Google Scholar 

  10. National Institute for Sickness and Invalidity Insurance (INAMI/RIZIV). Brussels 2002

  11. Lederle F. Epidemiology of constipation in elderly patients: drug utilisation and cost-containment strategies. Drugs Aging 1995; 6(6): 465–9

    Article  PubMed  CAS  Google Scholar 

  12. Tramonte S, Brand M, Mulrow C, et al. The treatment of chronic constipation in adults: a systematic review. J Gen Intern Med 1997; 12: 15–24

    Article  PubMed  CAS  Google Scholar 

  13. Sweeney M. Constipation: diagnosis and treatment. Home Care Provid 1997; 2(5): 250–5

    Article  PubMed  CAS  Google Scholar 

  14. Weinstein MC, Fineberg HV. Clinical decision analysis. Philadelphia: WB Saunders Co., 1980: 228–65

    Google Scholar 

  15. Denis P, Teillet L, Moulias R-L. Tolérance et efficacité du Forlax: Étude comparative versus lactulose au long cours chez des patients souffrant de constipation functionnelle. Act Med Int Gastro-enterologie 1996; 10 Suppl. 2: 3–14

    Google Scholar 

  16. Couturier D, Licht H. Etude comparative de l’efficacité de Forlax versus lactulose dans le traitement de la constipation fonctionnelle de l’adulte. Gastroenterologie 1996; 105: 21–4

    Google Scholar 

  17. Flourie B. Treatment of constipation by macrogol 3350: preliminary study on healthy volunteers (the impact of the concentration and method of administration of the solution on the weight and osmolarity of stools). Norgine Ltd, 1991 (data on file)

  18. Lémann M, Chaussade S, Halphen M, et al. Low dose polyethylene glycol in chronic constipation: double-blind placebo-controlled crossover trial [abstract]. Gastroenterology 1996; 110: A704

    Google Scholar 

  19. Bouhnik Y, Neut C, Raskine L, et al. Prospective, randomized, parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation. Aliment Pharmacol Ther 2004; 19(8): 889–99

    Article  PubMed  CAS  Google Scholar 

  20. Passmore A. Economic aspects of pharmacotherapy for chronic constipation. Pharmacoeconomics 1995; 7(1): 14–24

    Article  PubMed  CAS  Google Scholar 

  21. Lederle FA, Busch DL, Mattox KM, et al. Cost-effective treatment of constipation in the elderly: a randomized double-blind comparison of sorbitol and lactulose. Am J Med 1990; 89(5): 597–601

    Article  PubMed  CAS  Google Scholar 

  22. Frank L, Kleinman L, Farup L, et al. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol 1999; 34: 870–7

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors would like to thank the following specialists for their contributions: Dr T De Ronde, UCL de Mont-Godinne, Yvoir; Dr M Ferrante, Hospital St Martin, Mechelen; Dr El Nawar, CHR Hospital, Mouscron; Dr C Feys, Jan Yperman Hospital, Ypres; Dr P Laukens, AZ Hospital, Bruges; Dr Lamy, CHU Hospital, Jumet; Dr E Louis, CHU de Liege, Liege; Dr J Stubbe, Onze Lieve Vrouw Hospital, Aalst; Dr E Vanderstraeten, Volksklineik Hospital, Ghent; Dr A Van Gossum, Hospital Erasme, Brussels; Dr M Van Outryve, Antwerp. The authors would also like to thank the following GPs for their contributions: Dr M Bailly, Liege; Dr D Bruls, Robertville; Dr P Derache, Jumet (Charleroi); Dr P Jadoul, Jambes (Namur); Dr V Martens, Antwerpen; Dr P Nevejan, Hooglede; Dr R Roggen, Zoutleeuw; Dr M Salavracos, Bruxelles; Dr E Schulzen, Saint-Vith; Dr B Van Bostraeten, Lier; Dr J Van Neck, Aalst.

The authors also thank Norgine for their financial support of this study. The authors have no conflicts of interests directly relevant to the content of this manuscript.

Author information

Authors and Affiliations

  1. CATALYST Health Economics Consultants, 34b High Street, Northwood, Middlesex, HA6 1BN, UK

    Julian F. Guest & Susan J. Varney

Authors
  1. Julian F. Guest
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan J. Varney
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Julian F. Guest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Guest, J.F., Varney, S.J. Pharmacoeconomic Impact of Low-Dose Macrogol 3350 plus Electrolytes Compared with Lactulose in the Management of Chronic Idiopathic Constipation among Ambulant Patients in Belgium. Clin. Drug Investig. 24, 719–729 (2004). https://doi.org/10.2165/00044011-200424120-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200424120-00003

Keywords

Search

Navigation